Scarica l'app Stockscreener
63.34
2.85%
-1.86
Precedente Chiudi:
$65.20
Aprire:
$64.99
Volume 24 ore:
668.46K
Relative Volume:
0.77
Capitalizzazione di mercato:
$3.66B
Reddito:
$76.81M
Utile/perdita netta:
$-162.42M
Rapporto P/E:
-21.18
EPS:
-2.99
Flusso di cassa netto:
$-122.49M
1 W Prestazione:
-3.61%
1M Prestazione:
-7.95%
6M Prestazione:
-4.52%
1 anno Prestazione:
-19.57%
Intervallo 1D:
$62.88
$65.97
Intervallo di 1 settimana:
$62.88
$65.97
Portata 52W:
$47.86
$94.07
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Confronta ACLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
63.34 | 3.77B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital - MSN
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8% - MarketBeat
Arcellx Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (ACLX) Movement - Stock Traders Daily
EPS Watch: Can Arcellx Inc stock reach 100 price target2025 Volume Leaders & Community Trade Idea Sharing Platform - moha.gov.vn
Wells starts Arcellx with overweight on multiple myeloma potential - MSN
Arcellx (NASDAQ:ACLX) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program - Yahoo Finance
Wells Fargo initiates coverage of Arcellx (ACLX) with overweight recommendation - MSN
Wells Fargo Initiates Coverage of Arcellx (ACLX) with Overweight Recommendation - Nasdaq
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - Seeking Alpha
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls - Yahoo Finance
Voya Investment Management LLC Reduces Stock Holdings in Arcellx, Inc. $ACLX - MarketBeat
Wells Fargo Initiates Arcellx at Overweight With $100 Price Target - marketscreener.com
Wells Fargo initiates coverage on Arcellx stock with Overweight rating By Investing.com - Investing.com Canada
Wells Fargo initiates coverage on Arcellx stock with Overweight rating - Investing.com
Wells starts Arcellx with Overweight on multiple myeloma potential - TipRanks
Arcellx initiated with an Overweight at Wells Fargo - TipRanks
Can Arcellx Inc. stock continue upward trendJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда
Is Arcellx Inc. stock affected by interest rate hikesQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is Arcellx Inc. stock a defensive play in 2025July 2025 PreEarnings & Technical Entry and Exit Tips - Улправда
How institutional buying supports Arcellx Inc. stock2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Earnings Report: Is Arcellx Inc. stock attractive for hedge funds2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will Arcellx Inc. stock benefit from commodity pricesTake Profit & Breakout Confirmation Trade Signals - Улправда
Why Arcellx Inc. stock could benefit from AI revolutionJuly 2025 Macro Moves & Safe Capital Growth Plans - DonanımHaber
Why Arcellx Inc. stock is recommended by analysts2025 Historical Comparison & Daily Profit Maximizing Trade Tips - DonanımHaber
Dividend Watch: Why Arcellx Inc. stock could see breakout soonDip Buying & AI Powered Buy and Sell Recommendations - Улправда
Technical Reactions to ACLX Trends in Macro Strategies - Stock Traders Daily
Is Arcellx Inc. stock attractive for hedge fundsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Arcellx, Inc. (ACLX) makes progress on multiple myeloma treatment - MSN
Arcellx: Funded Into 2028 With Strong Clinical Data (NASDAQ:ACLX) - Seeking Alpha
Canaccord Genuity Reaffirms Their Buy Rating on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx reports promising phase 2 study results - MSN
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment - Finviz
What Arcellx (ACLX)'s Anito‑cel Phase 2 Data Means For Shareholders - simplywall.st
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Positive Outlook for Arcellx Inc: Buy Rating Backed by Strategic Positioning and Promising CAR T-cell Therapy - TipRanks
Stempoint Capital LP Has $13.27 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Citi Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness By Investing.com - Investing.com South Africa
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness - Investing.com
Cancer Study Buoys These Small Biotechs - Barron's
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025 - ts2.tech
Arcellx shares jump on strong multiple myeloma trial results - MSN
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM - Clinical Trials Arena
Arcellx (ACLX) Valuation Check After Strong Phase 2 iMMagine-1 Results for Anito-cel in Multiple Myeloma - Sahm
Arcellx Inc. Stock Surge: Time to Buy? - StocksToTrade
Arcellx Reports Promising Phase 2 Study Results - TipRanks
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):